Authors: Passi, P Zadro, A Marsilio, F Lora, S Caliceti, P Veronese, FM

Citation: P. Passi et al., Plain and drug loaded polyphosphazene membranes and microspheres in the treatment of rabbit bone defects, J MAT S-M M, 11(10), 2000, pp. 643-654

Authors: Boni, C Bisagni, G Savoldi, L Moretti, G Rondini, E Sassi, M Zadro, A De Pas, T Franciosi, V Pazzola, A Vignoli, R Banzi, MC Pajetta, V

Citation: C. Boni et al., Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group forclinical research (GOIRC), INT J CANC, 87(5), 2000, pp. 724-727

Authors: Cocconi, G Bisagni, G Ceci, G Blasio, BD De Lisi, V Passalacqua, R Zadro, A Boni, C Morandi, P Savoldi, L

Citation: G. Cocconi et al., Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial, BREAST CANC, 56(2), 1999, pp. 125-132

Authors: Boni, C Savoldi, L Bisagni, G Ceci, G Crino, L De Lisi, V Di Costanzo, F Lasagni, L Manenti, AL Moretti, G Rondini, E Sassi, M Zadro, A

Citation: C. Boni et al., Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): A phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC), EUR J CANC, 34(12), 1998, pp. 1974-1976

Authors: Bisagni, G Boni, C Manenti, AL Moretti, G Rondini, E Sassi, M Zadro, A Savoldi, L

Citation: G. Bisagni et al., Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: A phase II study, TUMORI, 84(6), 1998, pp. 659-661